217 related articles for article (PubMed ID: 25445703)
1. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer.
Choi SH; Byeon HJ; Choi JS; Thao L; Kim I; Lee ES; Shin BS; Lee KC; Youn YS
J Control Release; 2015 Jan; 197():199-207. PubMed ID: 25445703
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer.
Kim I; Byeon HJ; Kim TH; Lee ES; Oh KT; Shin BS; Lee KC; Youn YS
Biomaterials; 2013 Sep; 34(27):6444-53. PubMed ID: 23755831
[TBL] [Abstract][Full Text] [Related]
3. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types.
Bae S; Ma K; Kim TH; Lee ES; Oh KT; Park ES; Lee KC; Youn YS
Biomaterials; 2012 Feb; 33(5):1536-46. PubMed ID: 22118776
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution.
Kim TH; Jiang HH; Youn YS; Park CW; Lim SM; Jin CH; Tak KK; Lee HS; Lee KC
J Pharm Sci; 2011 Feb; 100(2):482-91. PubMed ID: 20669330
[TBL] [Abstract][Full Text] [Related]
6. A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.
Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Jiang X
Nanotechnology; 2011 Jul; 22(26):265105. PubMed ID: 21586819
[TBL] [Abstract][Full Text] [Related]
7. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model.
Roa WH; Azarmi S; Al-Hallak MH; Finlay WH; Magliocco AM; Löbenberg R
J Control Release; 2011 Feb; 150(1):49-55. PubMed ID: 21059378
[TBL] [Abstract][Full Text] [Related]
8. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
[TBL] [Abstract][Full Text] [Related]
9. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy.
Jiang HH; Kim TH; Lee S; Chen X; Youn YS; Lee KC
Biomaterials; 2011 Nov; 32(33):8529-37. PubMed ID: 21855130
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained- release inhalation system for the treatment of metastatic lung cancer.
Kim I; Byeon HJ; Kim TH; Lee ES; Oh KT; Shin BS; Lee KC; Youn YS
Biomaterials; 2012 Aug; 33(22):5574-83. PubMed ID: 22579235
[TBL] [Abstract][Full Text] [Related]
11. Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo.
Al-Jamal KT; Al-Jamal WT; Wang JT; Rubio N; Buddle J; Gathercole D; Zloh M; Kostarelos K
ACS Nano; 2013 Mar; 7(3):1905-17. PubMed ID: 23527750
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
13. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis.
Aroui S; Brahim S; Hamelin J; De Waard M; Bréard J; Kenani A
Apoptosis; 2009 Nov; 14(11):1352-65. PubMed ID: 19731037
[TBL] [Abstract][Full Text] [Related]
14. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles.
Azarmi S; Tao X; Chen H; Wang Z; Finlay WH; Löbenberg R; Roa WH
Int J Pharm; 2006 Aug; 319(1-2):155-61. PubMed ID: 16713150
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
16. Secondary cytotoxicity mediated by alveolar macrophages: a contribution to the total efficacy of nanoparticles in lung cancer therapy?
Al-Hallak KM; Azarmi S; Anwar-Mohamed A; Roa WH; Löbenberg R
Eur J Pharm Biopharm; 2010 Sep; 76(1):112-9. PubMed ID: 20452423
[TBL] [Abstract][Full Text] [Related]
17. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles.
Lim SM; Kim TH; Jiang HH; Park CW; Lee S; Chen X; Lee KC
Biomaterials; 2011 May; 32(13):3538-46. PubMed ID: 21306770
[TBL] [Abstract][Full Text] [Related]
18. Distribution of effervescent inhalable nanoparticles after pulmonary delivery: an in vivo study.
Al-Hallak MH; Sarfraz MK; Azarmi S; Roa WH; Finlay WH; Rouleau C; Löbenberg R
Ther Deliv; 2012 Jun; 3(6):725-34. PubMed ID: 22838068
[TBL] [Abstract][Full Text] [Related]
19. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo.
Han HS; Lee J; Kim HR; Chae SY; Kim M; Saravanakumar G; Yoon HY; You DG; Ko H; Kim K; Kwon IC; Park JC; Park JH
J Control Release; 2013 Jun; 168(2):105-14. PubMed ID: 23474029
[TBL] [Abstract][Full Text] [Related]
20. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
Misra R; Sahoo SK
Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
